Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRd induction followed by cilta-cel versus VRd followed by Rd in transplant-ineligible newly diagnosed multiple myeloma
NL-OMON59604Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ciltacabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Mar 2022; status: active, not recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON59604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59604.